msn exelixis news - Search News

Exelixis gains

Exelixis gains after win in patent fight with MSN over Cabometyx

Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claim of the '349 patent not infringed and not invalid, Judge Richard Andrews ruled,

Zacks.com on MSN · 1d

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

Exelixis, Inc. EXEL announced that the District Court of Delaware has ruled in its favor in the second patent litigation against MSN Laboratories. MSN is seeking approval for its generic product of Exelixis’ cabozantinib.

Business Wire · 1d

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A

MarketWatch · 1d

Exelixis' Wins Court Ruling in Patent-Infringement Lawsuit

A court ruled in favor of Exelixis in the oncology company's patent-infringement lawsuit against MSN Laboratories.

Business Insider · 1d

Exelixis Strengthened by Favorable Patent Ruling and Pipeline Prospects, Price Target Raised to $33

Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $33.00. Akash

Hosted on MSN23h

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Exelixis EXEL shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

GlobalData on MSN2d

Exelixis and MSD to trial cancer therapies together in clinical collaboration

US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...

FiercePharma1d

Exelixis stock rises as key drug Cabometyx withstands patent challenge

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Zacks.com on MSN2d

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...

13h

Exelixis: Navigating Patent Challenges and Future Growth Prospects with a Hold Rating

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Hosted on MSN10d

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Shares of Exelixis, Inc. EXEL have risen 20.7% in the past three months compared with the industry’s growth of 6.3%. The ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results